Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Near-Infrared Spectral Tomography for Predicting Residual Cancer Burden during Early-Stage Neoadjuvant Chemotherapy for Breast Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 28, 2023
Estrogen therapy induces receptor-dependent DNA damage enhanced by PARP inhibition in ER+ breast cancer.
Journal: bioRxiv : the preprint server for biology
Published: March 30, 2023
Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 27, 2023
Alternating 17β-Estradiol and Aromatase Inhibitor Therapies Is Efficacious in Postmenopausal Women with Advanced Endocrine-Resistant ER+ Breast Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 13, 2023
Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: November 04, 2022
Preventing metastatic recurrence in low-risk ER/PR + breast cancer patients-a retrospective clinical study exploring the evolving challenge of persistence with adjuvant endocrine therapy.
Journal: Breast cancer research and treatment
Published: September 20, 2022
Plasma DNA as a "liquid biopsy" incompletely complements tumor biopsy for identification of mutations in a case series of four patients with oligometastatic breast cancer.
Journal: Breast cancer research and treatment
Published: March 18, 2020
Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center.
Journal: The oncologist
Published: March 13, 2015
Clinical and Translational Results of a Phase II, Randomized Trial of an Anti-IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 12, 2015
The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.
Journal: Breast cancer research and treatment
Published: September 24, 2014
Stromal expression of miR-21 identifies high-risk group in triple-negative breast cancer.
Journal: The American journal of pathology
Published: July 09, 2014
Last Updated: 09/26/2026